BLTE Logo

Belite Bio, Inc (BLTE) Stock Forecast & Price Prediction

Live BLTE Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$58.07

+0.01 (0.02%)

12 Month Price Forecast For BLTE

$58.07
Current Price
$1.82B
Market Cap
5 Ratings
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to BLTE Price Forecasts

+89.4%
To High Target of $110.00
+54.1%
To Median Target of $89.50
-13.9%
To Low Target of $50.00

BLTE Price Momentum

-2.6%
1 Week Change
-1.1%
1 Month Change
+29.3%
1 Year Change
-8.0%
Year-to-Date Change
-32.9%
From 52W High of $86.53
+87.3%
From 52W Low of $31.00

๐Ÿค” Considering Belite Bio (BLTE)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 6, 2025 11:57 AM UTC

BLTE Analyst Ratings & Price Targets

Based on our analysis of 6 Wall Street analysts, BLTE has a consensus that is bullish. The median price target is $89.50, with forecasts ranging from $50.00 to $110.00. Currently, there are 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.

With BLTE currently trading at $58.07, the median price forecast suggests a 54.1% upside. The most optimistic forecast comes from Jason McCarthy at Maxim Group, projecting a 89.4% upside, while at provides the most conservative target, suggesting a -13.9% downside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

BLTE Analyst Consensus

5
Buy
0
Hold
0
Sell

BLTE Price Target Range

Low
$50.00
Average
$89.50
High
$110.00
Current: $58.07

Latest BLTE Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for BLTE.

Date Firm Analyst Rating Change Price Target
Jan 21, 2025 Benchmark Bruce Jackson Buy Maintains $79.00
Nov 15, 2024 Maxim Group Jason McCarthy Buy Maintains $110.00
Nov 13, 2024 HC Wainwright & Co. Yi Chen Buy Maintains $100.00
Sep 12, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $60.00
Aug 13, 2024 HC Wainwright & Co. Yi Chen Buy Maintains $60.00
Aug 13, 2024 Benchmark Bruce Jackson Buy Reiterates $57.00
Jun 20, 2024 Cantor Fitzgerald Jennifer Kim Overweight Reiterates $0.00
Jun 13, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $59.00
May 16, 2024 Benchmark Bruce Jackson Buy Reiterates $57.00
May 15, 2024 Cantor Fitzgerald Jennifer Kim Overweight Reiterates $0.00
May 15, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $59.00
Mar 22, 2024 HC Wainwright & Co. Yi Chen Buy Maintains $59.00
Mar 13, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $59.00
Dec 27, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $59.00
Dec 14, 2023 Maxim Group Jason McCarthy Buy Initiates $60.00
Nov 15, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $59.00
Nov 7, 2023 Benchmark Bruce Jackson Buy Reiterates $57.00
Nov 6, 2023 HC Wainwright & Co. Yi Chen Buy Maintains $59.00
Aug 10, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $55.00
Jul 28, 2023 Cantor Fitzgerald Jennifer Kim Overweight Initiates $43.00

Stocks Similar to Belite Bio, Inc

The following stocks are similar to Belite Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Belite Bio, Inc (BLTE) Financial Data

Belite Bio, Inc has a market capitalization of $1.82B with a P/E ratio of -48.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -40.0%.

Valuation Metrics

Market Cap $1.82B
Enterprise Value $1.73B
P/E Ratio -48.8x
PEG Ratio -59.6x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio 0.0%
Current Ratio 30.7x
Debt/Equity 0.0x
ROE -40.0%
ROA -25.6%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Belite Bio, Inc logo

Belite Bio, Inc (BLTE) Company Overview

About Belite Bio, Inc

What They Do

Develops therapeutics for retinal degenerative diseases.

Business Model

Belite Bio, Inc. operates as a clinical-stage biopharmaceutical company focused on researching and developing innovative therapies for retinal degenerative eye diseases. The company primarily generates revenue through the advancement of its drug candidates, such as LBS-008 and LBS-009, which aim to address significant unmet medical needs in the market.

Additional Information

Founded in 2016 and based in San Diego, California, Belite Bio is a subsidiary of Lin Bioscience International Ltd. Its lead product, LBS-008, is designed for once-daily oral administration and targets specific eye conditions, while LBS-009 is in preclinical development for liver-related diseases and type 2 diabetes.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

20

CEO

Dr. Yu-Hsin Lin M.B.A., Ph.D.

Country

United States

IPO Year

2022

Belite Bio, Inc (BLTE) Latest News & Analysis

BLTE stock latest news image
Quick Summary

Lin BioScience's LBS-007 has received Fast Track Designation from the FDA for acute myeloid leukemia. The company is conducting a phase 1/2 trial and holds orphan drug designations for both AML and ALL.

Why It Matters

Lin BioScience's Fast Track Designation for LBS-007 enhances its potential for accelerated market access, increasing investor confidence and interest in its future growth and profitability.

Source: GlobeNewsWire
Market Sentiment: Neutral
BLTE stock latest news image
Quick Summary

Belite Bio, Inc. (NASDAQ:BLTE) will hold its Q3 2024 earnings conference call on November 12, 2024, at 4:30 PM ET, featuring key executives and analysts from various firms.

Why It Matters

Belite Bio's Q3 earnings call will provide insights into its financial health and strategic direction, impacting stock performance and investor sentiment.

Source: Seeking Alpha
Market Sentiment: Neutral
BLTE stock latest news image
Quick Summary

Belite Bio, Inc (NASDAQ: BLTE) will host a webcast on November 12, 2024, at 4:30 p.m. ET to discuss Q3 2024 financial results and provide a business update.

Why It Matters

Belite Bio's upcoming webcast will reveal key financial results and business developments, impacting investor sentiment and stock performance for the clinical-stage biopharmaceutical company.

Source: GlobeNewsWire
Market Sentiment: Neutral
BLTE stock latest news image
Quick Summary

Belite Bio has entered into an agreement to exercise warrants for 651,380 shares at $44.14 each, raising approximately $28.75 million for general corporate purposes.

Why It Matters

Belite Bio's warrant exercise indicates strong investor confidence, raising $28.75 million for development. This financial boost can accelerate research, impacting future growth and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
BLTE stock latest news image
Quick Summary

Belite Bio (NASDAQ: BLTE) appointed Dr. Hendrik P. N. Scholl as Chief Medical Officer, effective immediately. He is an expert in Stargardt disease and AMD, key areas for Belite's lead drug, Tinlarebant.

Why It Matters

The appointment of a renowned expert as CMO enhances Belite Bio's credibility and could accelerate drug development, potentially leading to increased investor confidence and stock value.

Source: GlobeNewsWire
Market Sentiment: Neutral
BLTE stock latest news image
Quick Summary

Belite Bio, Inc (NASDAQ:BLTE) will hold its Q2 2024 earnings conference call on August 12, 2024, at 4:30 PM ET, featuring key executives and analysts from various firms.

Why It Matters

The Q2 2024 earnings call for Belite Bio will provide insights into the company's financial performance and strategic direction, influencing investor sentiment and stock valuation.

Source: Seeking Alpha
Market Sentiment: Neutral

Frequently Asked Questions About BLTE Stock

What is Belite Bio, Inc's (BLTE) stock forecast for 2025?

Based on our analysis of 6 Wall Street analysts, Belite Bio, Inc (BLTE) has a median price target of $89.50. The highest price target is $110.00 and the lowest is $50.00.

Is BLTE stock a good investment in 2025?

According to current analyst ratings, BLTE has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $58.07. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for BLTE stock?

Wall Street analysts predict BLTE stock could reach $89.50 in the next 12 months. This represents a 54.1% increase from the current price of $58.07. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Belite Bio, Inc's business model?

Belite Bio, Inc. operates as a clinical-stage biopharmaceutical company focused on researching and developing innovative therapies for retinal degenerative eye diseases. The company primarily generates revenue through the advancement of its drug candidates, such as LBS-008 and LBS-009, which aim to address significant unmet medical needs in the market.

What is the highest forecasted price for BLTE Belite Bio, Inc?

The highest price target for BLTE is $110.00 from Jason McCarthy at Maxim Group, which represents a 89.4% increase from the current price of $58.07.

What is the lowest forecasted price for BLTE Belite Bio, Inc?

The lowest price target for BLTE is $50.00 from at , which represents a -13.9% decrease from the current price of $58.07.

What is the overall BLTE consensus from analysts for Belite Bio, Inc?

The overall analyst consensus for BLTE is bullish. Out of 6 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $89.50.

How accurate are BLTE stock price projections?

Stock price projections, including those for Belite Bio, Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.